Jeanne Palmer

11.0k total citations
153 papers, 2.9k citations indexed

About

Jeanne Palmer is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Jeanne Palmer has authored 153 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Hematology, 64 papers in Genetics and 24 papers in Oncology. Recurrent topics in Jeanne Palmer's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (57 papers), Hematopoietic Stem Cell Transplantation (48 papers) and Acute Myeloid Leukemia Research (45 papers). Jeanne Palmer is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (57 papers), Hematopoietic Stem Cell Transplantation (48 papers) and Acute Myeloid Leukemia Research (45 papers). Jeanne Palmer collaborates with scholars based in United States, United Kingdom and Italy. Jeanne Palmer's co-authors include Joseph Pidala, Stephanie J. Lee, Madan Jagasia, Xiaoyu Chai, Corey Cutler, Steven Z. Pavletic, David A. Jacobsohn, Mary E.D. Flowers, Navneet S. Majhail and Sally Arai and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jeanne Palmer

135 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeanne Palmer United States	30	2.0k	695	605	561	559	153	2.9k
Wael Saber United States	31	2.7k 1.3×	612 0.9×	869 1.4×	822 1.5×	667 1.2×	173	3.7k
David Gómez‐Almaguer Mexico	29	1.9k 0.9×	700 1.0×	579 1.0×	741 1.3×	523 0.9×	335	3.0k
Hiroyasu Ogawa Japan	33	1.8k 0.9×	442 0.6×	882 1.5×	517 0.9×	735 1.3×	153	3.0k
Selim Corbacioglu Germany	29	1.4k 0.7×	428 0.6×	643 1.1×	389 0.7×	459 0.8×	105	2.7k
Joseph P. Uberti United States	27	1.5k 0.8×	762 1.1×	871 1.4×	291 0.5×	803 1.4×	159	3.0k
Shelly Carter United States	18	1.5k 0.7×	542 0.8×	433 0.7×	305 0.5×	661 1.2×	25	2.1k
José Carlos Jaime‐Pérez Mexico	25	1.3k 0.6×	472 0.7×	408 0.7×	512 0.9×	365 0.7×	182	2.2k
Steven L. McAfee United States	30	1.9k 0.9×	437 0.6×	1.2k 2.0×	748 1.3×	1.1k 2.0×	103	3.7k
Renate Arnold Germany	25	1.4k 0.7×	299 0.4×	466 0.8×	714 1.3×	696 1.2×	77	2.4k
Pablo Parker United States	25	1.6k 0.8×	229 0.3×	520 0.9×	488 0.9×	645 1.2×	51	2.2k

Countries citing papers authored by Jeanne Palmer

Since Specialization

Citations

This map shows the geographic impact of Jeanne Palmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeanne Palmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeanne Palmer more than expected).

Fields of papers citing papers by Jeanne Palmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeanne Palmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeanne Palmer. The network helps show where Jeanne Palmer may publish in the future.

Co-authorship network of co-authors of Jeanne Palmer

This figure shows the co-authorship network connecting the top 25 collaborators of Jeanne Palmer. A scholar is included among the top collaborators of Jeanne Palmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeanne Palmer. Jeanne Palmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kusne, Yael, Talha Badar, Terra L. Lasho, et al.. (2025). Prevalence of cytopenia(s) and somatic variants in patients with DDX41 mutant germline predisposition syndrome. British Journal of Haematology. 206(4). 1109–1120. 2 indexed citations

Baranwal, Anmol, Mohamed A. Kharfan‐Dabaja, Ernesto Ayala, et al.. (2024). Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide. Transplantation and Cellular Therapy. 31(1). 16.e1–16.e9.

Kusne, Yael, Talha Badar, Terra L. Lasho, et al.. (2024). Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome. Blood. 144(Supplement 1). 440–440.

Badar, Talha, James M. Foran, Mohamed A. Kharfan‐Dabaja, et al.. (2024). Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53-mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series. Blood. 144(Supplement 1). 1823–1823. 1 indexed citations

Pemmaraju, Naveen, Marina Kremyanskaya, Andrew Kuykendall, et al.. (2023). MPN-541 Targeted Therapy of Uncontrolled Erythrocytosis in Polycythemia Vera With the Hepcidin Mimetic, Rusfertide: Blinded Randomized Withdrawal Results of the Phase 2 Revive Study. Clinical Lymphoma Myeloma & Leukemia. 23. S400–S401.

Baranwal, Anmol, Khaled Ali, Mohamed A. Kharfan‐Dabaja, et al.. (2023). Surrogates of Endothelial Injury Predict Non-Relapse Mortality Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis. Transplantation and Cellular Therapy. 29(2). S9–S10. 1 indexed citations

Bewersdorf, Jan Philipp, Claire Harrison, Francesca Palandri, et al.. (2023). Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.. Journal of Clinical Oncology. 41(16_suppl). 7018–7018. 1 indexed citations

Ensign, Shannon P. Fortin, et al.. (2023). Histiocytic Sarcoma Treated with Pembrolizumab: A Case Report and Literature Review. SHILAP Revista de lepidopterología. 6(4). 198–202. 4 indexed citations

Tibes, Raoul, Heidi Kosiorek, Amylou C. Dueck, et al.. (2023). Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms. Cancer. 129(15). 2321–2330. 7 indexed citations

10.

Al‐Kali, Aref, Raoul Tibes, Pamela J. Atherton, et al.. (2023). A phase II study of combination daunorubicin, cytarabine (Ara‐c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression. American Journal of Hematology. 98(3). 472–480. 5 indexed citations

11.

Baranwal, Anmol, Rong He, David S. Viswanatha, et al.. (2023). Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms. Blood Advances. 8(3). 562–570. 1 indexed citations

12.

Abedin, Sameem, Mark A. Schroeder, Rizwan Romee, et al.. (2021). Ruxolitinib resistance or intolerance in steroid‐refractory acute graft‐versus‐host disease — a real‐world outcomes analysis. British Journal of Haematology. 195(3). 429–432. 10 indexed citations

13.

Mascarenhas, John, Francesco Passamonti, Kate Burbury, et al.. (2021). The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. Blood Advances. 6(4). 1162–1174. 16 indexed citations

14.

Jain, Tania, Katie L. Kunze, Luke Mountjoy, et al.. (2020). Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis. Blood Cancer Journal. 10(3). 36–36. 13 indexed citations

15.

Palmer, Jeanne, Heidi Kosiorek, Christine Wolschke, et al.. (2019). Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis. Biology of Blood and Marrow Transplantation. 25(11). 2267–2273. 5 indexed citations

16.

Tefferi, Ayalew, Jeanne Palmer, James L. Slack, et al.. (2018). Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. American Journal of Hematology. 93(5). 649–654. 28 indexed citations

17.

Jain, Tania, Fares Alahdab, Belal Firwana, et al.. (2018). Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation. 25(4). 728–733. 15 indexed citations

18.

Jain, Tania, Mohamad Bassam Sonbol, Belal Firwana, et al.. (2018). High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation. 25(2). 239–247. 24 indexed citations

19.

Kumar, Pawan, Kamalakannan Rajasekaran, Jeanne Palmer, Monica S. Thakar, & Subramaniam Malarkannan. (2013). IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration. Journal of Cancer. 4(1). 57–65. 36 indexed citations

20.

Münchau, Alexander, et al.. (1999). Selective peripheral denervation with posterior primary ramisectomy is useful for botulinum toxin resistant patients with cervical dystonia: Results of a prospective study. UCL Discovery (University College London). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact